Evidence map›Paper›PMID 40846860›Full record

ArticleNature communications2025

Chemically modified tRNA enhances the translation capacity of mRNA rich in cognate codons.

Liangzhen Dong, Jiayu Wang, Qing Xia

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. The impact of psuedouridine modification on human tRNA.Biochemical Society transactions · 2026
    Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Liangzhen Dong *State Key Laboratory of Natural and Biomimetic Drugs, Department of Molecular and Cellular Pharmacology, School of Pharmaceutical Sciences, Peking University, Beijing, China.ORCID http://orcid.org/0009-0007-6634-5502
Jiayu Wang *State Key Laboratory of Natural and Biomimetic Drugs, Department of Molecular and Cellular Pharmacology, School of Pharmaceutical Sciences, Peking University, Beijing, China.ORCID http://orcid.org/0009-0001-8404-1824
Qing XiaState Key Laboratory of Natural and Biomimetic Drugs, Department of Molecular and Cellular Pharmacology, School of Pharmaceutical Sciences, Peking University, Beijing, China. xqing@hsc.pku.edu.cn.ORCID http://orcid.org/0000-0002-8191-7712

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although messenger RNA (mRNA) vaccines have been employed to prevent the spread of COVID-19, they are still limited by instability and low translation capacity. Alterations in tRNA abundance and modification, linking codon optimality, impact mRNA stability and protein output in a codon-dependent manner, suggesting tRNA as a potential translation enhancer. Here, we report a strategy named tRNA-plus to augment translation via artificially modulating tRNA availability. Overexpression of specific tRNAs enhances the stability and translation efficiency of SARS-CoV-2 Spike mRNA, boosting protein levels up to 4.7-fold. Additionally, chemically synthesized tRNAs bearing multiple site-specific modifications, particularly at the anticodon-loop and TΨC-loop, exhibit on average ~4-fold higher decoding efficacy than unmodified tRNAs, along with increased stability and reduced immunotoxicity. Furthermore, codelivery of Spike mRNA vaccine and tRNA through lipid nanoparticles elicits augmented humoral and cellular immune responses in vivo. These results presented here provide a general approach to elevate mRNA translation potency, with applications in diverse translation-based fields.

Indexed as

CodonProtein BiosynthesisRNA, MessengerRNA, TransferSARS-CoV-2AnimalsCOVID-19COVID-19 VaccinesFemaleHEK293 CellsHumansMiceMice, Inbred BALB CSpike Glycoprotein, CoronavirusCodonCOVID-19 VaccinesRNA, MessengerRNA, TransferSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2

Identifiers

PMID40846860
PMCPMC12373798

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.